Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 3, 2013, Pages 297-300

  Champlin, Richard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myeloid leukemia; allogeneic; AML; elderly; hematopoietic transplantation; nonmyeloablative; reduced intensity conditioning; stem cell transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; DISEASE FREE SURVIVAL; HEALTH CARE QUALITY; HEMATOPOIESIS; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; STEM CELL; TREATMENT OUTCOME;

ACUTE MYELOID LEUKEMIA; ALLOGENEIC; AML; ELDERLY; HEMATOPOIETIC TRANSPLANTATION; NONMYELOABLATIVE; REDUCED INTENSITY CONDITIONING; STEM CELL TRANSPLANTATION;

AGE FACTORS; AGED; GAMMA RAYS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MYELOABLATIVE AGONISTS; STANDARD OF CARE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84889661479     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.10.011     Document Type: Review

References (24)

1. H. Kantarjian, S. O'Brien, and J. Cortes Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome Cancer 106 2006 1090 1098
2. H. Dohner, E.H. Estey, and S. Amadori Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
3. F.R. Appelbaum, H. Gundacker, and D.R. Head Age and acute myeloid leukemia Blood 107 2006 3481 3485
4. J.M. Rowe, and M.S. Tallman How I treat acute myeloid leukemia Blood 116 2010 3147 3156
5. J. Koreth, R. Schlenk, and K.J. Kopecky Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials J Am Med Assoc 301 2009 2349 2361
6. E.D. Thomas Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases J Clin Oncol 1 1983 517 531
7. R.P. Gale, and R.E. Champlin How does bone-marrow transplantation cure leukaemia? Lancet 2 1984 28 30
8. M.M. Horowitz, R.P. Gale, and P.M. Sondel Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555 562
9. S. Giralt, E. Estey, and M. Albitar Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531 4536
10. S. Giralt, P.F. Thall, and I. Khouri Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631 637
11. R. Champlin, I. Khouri, and A. Shimoni Harnessing graft-versus- malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy Br J Haematol 111 2000 18 29
12. B. Oran, S. Giralt, and R. Saliba Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan Biol Blood Marrow Transplant 13 2007 454 462
13. B. Gyurkocza, R. Storb, and B.E. Storer Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia J Clin Oncol 28 2010 2859 2867
14. S. Tauro, C. Craddock, and K. Peggs Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia J Clin Oncol 23 2005 9387 9393
15. V. Gupta, M.S. Tallman, and W. He Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis Blood 116 2010 1839 1848
16. O. Ringden, M. Labopin, and G. Ehninger Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia J Clin Oncol 27 2009 4570 4577
17. B.L. Scott, B.M. Sandmaier, and B. Storer Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis Leukemia 20 2006 128 135
18. M. de Lima, A. Anagnostopoulos, and M. Munsell Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 104 2004 865 872
19. P. Chevallier, M. Labopin, and N. Milpied Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: A report from the acute leukemia working party of EBMT Bone Marrow Transplant 47 2012 1442 1447
20. U. Popat, H.E. Heslop, and A. Durett Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML) Bone Marrow Transplant 37 2006 547 552
21. B.L. McClune, D.J. Weisdorf, and T.L. Pedersen Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome J Clin Oncol 28 2010 1878 1887
22. E. Estey, M. de Lima, and R. Tibes Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 109 2007 1395 1400
23. S.S. Farag, K. Maharry, and M.J. Zhang Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission Biol Blood Marrow Transplant 17 2011 1796 1803
24. B. Gyurkocza, and F.R. Appelbaum Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation J Natl Compr Canc Netw 9 2011 319 329